Evommune (EVMN) Total Liabilities (2024 - 2026)

Evommune's (EVMN) quarterly Total Liabilities came in at $17.9 million in Q1 2026, down 7.64% on a QoQ basis from $19.4 million in Q4 2025.

Evommune (EVMN) Total Liabilities (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Total Liabilities data on file, last reported at $17.9 million in Q1 2026.

On a quarterly basis, Total Liabilities changed N/A year-over-year to $17.9 million in Q1 2026; TTM through Mar 2026 was $17.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $19.4 million, down 32.04% from the prior year.
Total Liabilities for Q1 2026 stood at $17.9 million, down from $19.4 million in the prior quarter.
Over the last five years, Total Liabilities for EVMN reached as high as $28.5 million in Q4 2024 and fell as low as $10.7 million in Q3 2025.
Historically, Total Liabilities has averaged $19.1 million across 3 years, with a median of $18.6 million in 2025.
On a YoY basis, Total Liabilities climbed as much as 32.04% in 2025 and fell as far as 32.04% in 2025.
Year by year, Total Liabilities stood at $28.5 million in 2024, then plunged by 32.04% to $19.4 million in 2025, then fell by 7.64% to $17.9 million in 2026.
Per Business Quant data, the three most recent Total Liabilities figures were $17.9 million in Q1 2026, $19.4 million in Q4 2025, and $10.7 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	60.46 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	177.22 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	3.79 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	7.33 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	7.12 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.45 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	15.48 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.62 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	753.82 Mn
10	Evommune	381.48 Mn	170.02 Mn	-	17.90 Mn

Download Data